Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?
作者信息
Ippolito Matthew M, Flexner Charles
机构信息
Division of Clinical Pharmacology, Department of Medicine and Department of Pharmacology & Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
出版信息
Clin Infect Dis. 2020 Dec 31;71(11):2965-2967. doi: 10.1093/cid/ciaa691.
Abstract
摘要
相似文献
1
Dose Optimization of Hydroxychloroquine for Coronavirus Infection 2019: Do Blood Concentrations Matter?2019年冠状病毒感染中羟氯喹的剂量优化：血药浓度重要吗？
Clin Infect Dis. 2020 Dec 31;71(11):2965-2967. doi: 10.1093/cid/ciaa691.
2
Hydroxychloroquine in the treatment of COVID-19: How to use it waiting for conclusive scientific evidence.羟氯喹治疗新型冠状病毒肺炎：在等待确凿科学证据期间如何使用
Med Clin (Barc). 2020 Aug 14;155(3):134-135. doi: 10.1016/j.medcli.2020.05.006. Epub 2020 May 16.
3
Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.氯喹和羟氯喹用于预防和治疗2019冠状病毒病：新希望与旧有的心血管问题
Kardiol Pol. 2020 Aug 25;78(7-8):811-817. doi: 10.33963/KP.15511. Epub 2020 Jul 14.
4
Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients.新出现的临床前证据不支持在新冠肺炎患者中广泛使用羟氯喹。
Nat Commun. 2020 Aug 26;11(1):4253. doi: 10.1038/s41467-020-17907-w.
5
Hydroxychloroquine-induced erythema multiforme in a patient with COVID-19.新冠病毒病患者中羟氯喹诱发的多形红斑
Med Clin (Barc). 2020 Sep 11;155(5):231. doi: 10.1016/j.medcli.2020.05.004. Epub 2020 May 19.
6
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics.一项实用随机对照试验报告称羟氯喹对 2019 年冠状病毒病病毒动力学无效。
Nat Commun. 2020 Oct 20;11(1):5284. doi: 10.1038/s41467-020-19056-6.
7
COVID-19 Pandemic - A Narrative Review of the Potential Roles of Chloroquine and Hydroxychloroquine.新型冠状病毒肺炎疫情：氯喹和羟氯喹潜在作用的叙事性综述。
Pain Physician. 2020 Aug;23(4S):S351-S366.
8
Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用
BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.
9
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
10
Will Hydroxychloroquine Still Be a Game-Changer for COVID-19 by Combining Azithromycin?羟氯喹联合阿奇霉素是否仍将成为 COVID-19 的游戏规则改变者？
Front Immunol. 2020 Aug 7;11:1969. doi: 10.3389/fimmu.2020.01969. eCollection 2020.
引用本文的文献
1
Analysis of Factors Influencing Whole Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus in China.中国系统性红斑狼疮患者全血羟氯喹浓度的影响因素分析
Rheumatol Ther. 2023 Dec;10(6):1597-1607. doi: 10.1007/s40744-023-00598-2. Epub 2023 Sep 27.
2
Hydroxychloroquine and azithromycin alter the contractility of living porcine heart slices.羟氯喹啉和阿奇霉素会改变猪活体心脏切片的收缩性。
Front Pharmacol. 2023 May 5;14:1127388. doi: 10.3389/fphar.2023.1127388. eCollection 2023.
3
Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials.羟氯喹和 COVID-19 患者的死亡率：观察性研究和随机对照试验的系统评价和荟萃分析。
Pathog Glob Health. 2021 Oct-Dec;115(7-8):456-466. doi: 10.1080/20477724.2021.1936818. Epub 2021 Jun 15.
本文引用的文献
1
Hydroxychloroquine in Coronavirus Disease 2019 Patients: What Still Needs to Be Known About the Kinetics.羟氯喹在 2019 年冠状病毒病患者中的应用：动力学方面仍有哪些未知。
Clin Infect Dis. 2020 Dec 31;71(11):2962-2964. doi: 10.1093/cid/ciaa558.
2
Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing.优化 COVID-19 患者的羟氯喹剂量：一种有效的药物再利用的综合建模方法。
Clin Pharmacol Ther. 2020 Aug;108(2):253-263. doi: 10.1002/cpt.1856. Epub 2020 May 12.
3
Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.优化重症监护病房新冠肺炎患者羟氯喹的给药方案
Clin Infect Dis. 2020 Nov 19;71(16):2227-2229. doi: 10.1093/cid/ciaa394.
4
No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection.对于重症新冠病毒感染患者，没有证据表明羟氯喹和阿奇霉素联合使用能实现快速的抗病毒清除或带来临床益处。
Med Mal Infect. 2020 Jun;50(4):384. doi: 10.1016/j.medmal.2020.03.006. Epub 2020 Mar 30.
5
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19：一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
6
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.突破：磷酸氯喹在临床研究中显示出对 COVID-19 相关肺炎的明显疗效。
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
7
Effect of Antiretroviral Therapy on Plasma Concentrations of Chloroquine and Desethyl-chloroquine.抗反转录病毒疗法对氯喹和去乙基氯喹血浆浓度的影响。
Clin Infect Dis. 2018 Oct 30;67(10):1617-1620. doi: 10.1093/cid/ciy405.
8
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.羟氯喹和氯喹在治疗系统性红斑狼疮、类风湿关节炎及相关疾病中的治疗和药理学特性。
Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.
9
The treatment of acute malaria with single oral doses of amodiaquin, chloroquine, hydroxychloroquine and pyrimethamine.单口服剂量阿莫地喹、氯喹、羟氯喹和乙胺嘧啶治疗急性疟疾。
Am J Trop Med Hyg. 1954 Sep;3(5):833-8. doi: 10.4269/ajtmh.1954.3.833.
10
Treatment of hydroxychloroquine overdose.羟氯喹过量的治疗。
Am J Emerg Med. 2001 Sep;19(5):420-4. doi: 10.1053/ajem.2001.25774.
Zotero 插件